PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.44%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
34.62%
G&A growth 1.1-1.25x TRVN's 30.38%. Bill Ackman would demand evidence of necessary spending.
No Data
No Data available this quarter, please select a different quarter.
-26.41%
Other expenses reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency.
14.45%
Operating expenses growth above 1.5x TRVN's 3.35%. Michael Burry would check for inefficiency.
14.45%
Total costs growth above 1.5x TRVN's 3.35%. Michael Burry would check for inefficiency.
561.32%
Interest expense growth above 1.5x TRVN's 6.74%. Michael Burry would check for over-leverage.
-26.41%
Both companies reducing D&A. Martin Whitman would check industry patterns.
55.40%
EBITDA growth exceeding 1.5x TRVN's 2.91%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-14.45%
Operating income decline while TRVN shows 1.37% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
231.19%
Other expenses growth 50-75% of TRVN's 359.66%. Bruce Berkowitz would examine cost efficiency.
43.33%
Pre-tax income growth exceeding 1.5x TRVN's 2.76%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
561.32%
Tax expense growth above 1.5x TRVN's 269.02%. Michael Burry would check for concerning trends.
43.33%
Net income growth exceeding 1.5x TRVN's 2.76%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
43.35%
EPS growth exceeding 1.5x TRVN's 2.72%. David Dodd would verify competitive advantages.
43.35%
Diluted EPS growth exceeding 1.5x TRVN's 2.72%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.